| Drug Name |
Sparfloxacin |
| Drug ID |
BADD_D02062 |
| Description |
Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. |
| Indications and Usage |
For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae). |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
J01MA09 |
| DrugBank ID |
DB01208
|
| KEGG ID |
D00590
|
| MeSH ID |
C061363
|
| PubChem ID |
60464
|
| TTD Drug ID |
D0K6GZ
|
| NDC Product Code |
Not Available |
| UNII |
Q90AGA787L
|
| Synonyms |
sparfloxacin | 5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)- 6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Zagam | PD 131501 | PD-131501 | AT 4140 | AT-4140 | CI 978 | CI-978 |
